201 related articles for article (PubMed ID: 6147448)
1. [Advances in the treatment of scleroderma].
Marquet R; Vilardell M
Med Clin (Barc); 1984 Jun; 83(2):74-7. PubMed ID: 6147448
[No Abstract] [Full Text] [Related]
2. The spectrum of scleroderma (II).
LeRoy EC; Lomeo R
Hosp Pract (Off Ed); 1989 Nov; 24(11):65-8, 69-72, 75-6 passim. PubMed ID: 2509504
[No Abstract] [Full Text] [Related]
3. The treatment of systemic sclerosis.
Black CM
Adv Exp Med Biol; 1999; 455():271-7. PubMed ID: 10599354
[No Abstract] [Full Text] [Related]
4. Drug treatment of scleroderma.
Leighton C
Drugs; 2001; 61(3):419-27. PubMed ID: 11293650
[TBL] [Abstract][Full Text] [Related]
5. Medical management of renal scleroderma.
Cannon PJ
N Engl J Med; 1978 Oct; 299(16):886-7. PubMed ID: 357974
[No Abstract] [Full Text] [Related]
6. [Raynaud syndrome].
Knorr M; Schmid A; steurer J; Vetter W
Schweiz Rundsch Med Prax; 1986 Jul; 75(29):893-6. PubMed ID: 3738337
[No Abstract] [Full Text] [Related]
7. [Treatment of scleroderma].
Mouthon L
Rev Prat; 2002 Nov; 52(17):1915-7. PubMed ID: 12532869
[TBL] [Abstract][Full Text] [Related]
8. Future targets in the management of systemic sclerosis.
Tyndall A; Matucci-Cerinic M; Müller-Ladner U
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii49-53. PubMed ID: 19487225
[TBL] [Abstract][Full Text] [Related]
9. Educational case report - self assessment.
Walker T
Cytopathology; 2002 Oct; 13(5):329. PubMed ID: 12421450
[No Abstract] [Full Text] [Related]
10. Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis.
Casale R; Generini S; Luppi F; Pignone A; Matucci-Cerinic M
Arthritis Rheum; 2004 Aug; 51(4):665-9. PubMed ID: 15334442
[No Abstract] [Full Text] [Related]
11. [Thermography with liquid crystal in scleroderma].
Tauchmannová H; Hajzok O
Z Rheumatol; 1977; 36(9-10):299-394. PubMed ID: 930425
[TBL] [Abstract][Full Text] [Related]
12. [Vasodilator treatment of chronic heart failure].
Woroszylska M
Kardiol Pol; 1983; 26(10):741-51. PubMed ID: 6141316
[No Abstract] [Full Text] [Related]
13. Systemic sclerosis: an update.
Varga J
Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
[TBL] [Abstract][Full Text] [Related]
14. Scleroderma: a case presentation.
Otterness S
Nephrol Nurs J; 2005; 32(4):454-6. PubMed ID: 16180790
[No Abstract] [Full Text] [Related]
15. Success of prednisone in the treatment of a patient with sarcoidosis and systemic sclerosis: Report of a case.
Borges da Costa J; Mayer-da-Silva A; Soares de Almeida LM; Marques Gomes M
Dermatol Online J; 2009 Mar; 15(3):11. PubMed ID: 19379655
[TBL] [Abstract][Full Text] [Related]
16. Management of systemic sclerosis.
Lim IG; Schrieber L
Isr Med Assoc J; 2002 Nov; 4(11 Suppl):953-7. PubMed ID: 12455189
[No Abstract] [Full Text] [Related]
17. [Pulmonary fibrosis, a major symptom of scleroderma. Histological data].
Barrière H; Moigneteau C; de Lajartre
Bull Soc Fr Dermatol Syphiligr; 1969; 76(2):239-41. PubMed ID: 5403411
[No Abstract] [Full Text] [Related]
18. [Kidney involvement in scleroderma].
Ritz E
Dtsch Med Wochenschr; 1981 Jan; 106(1):23-5. PubMed ID: 7449652
[No Abstract] [Full Text] [Related]
19. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation.
Cannon PJ; Hassar M; Case DB; Casarella WJ; Sommers SC; LeRoy EC
Medicine (Baltimore); 1974 Jan; 53(1):1-46. PubMed ID: 4808710
[No Abstract] [Full Text] [Related]
20. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
Henness S; Wigley FM
Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
